Ocular Dopamine Modulation for Neurological Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and neuropsychiatric disorders associated with altered dopamine function, such as Parkinson's disease, often lead to severe side effects and limited efficacy due to systemic administration of dopamine replacement therapies, which can cause dyskinesia and psychosis, and are invasive and costly.
Innovation Solution
Administering an agent that modulates neurotransmitter production or function directly to the eye, specifically targeting the retina, to increase dopamine production or inhibit melatonin production, using methods like intraocular injection, ophthalmic drops, or iontophoresis, with agents such as domperidone, haloperidol, or ML-23, to treat or prevent disorders like Parkinson's disease and schizophrenia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of dopamine replacement therapies is used, then dopamine function is restored in the brain, but severe side effects occur including dyskinesia and psychosis
Solution Approach 1:
The patent applies local quality by targeting the retina specifically rather than administering dopamine replacement systemically. The agent is administered directly to the eye to modulate neurotransmitter production in the retinal dopamine system, which has downstream projections to the brain. This localized approach restores dopamine function in the target area while avoiding the harmful systemic side effects associated with conventional dopamine replacement therapies.
2Reliability
If conventional systemic dopamine replacement therapies are administered, then neurological symptoms are treated, but the treatment is invasive and costly
Solution Approach 1:
The patent uses the eye/retina as an intermediary pathway to deliver the therapeutic agent to the brain's dopamine system. Instead of direct invasive brain surgery or complex systemic infusion, the agent is administered via a simple ocular route (intraocular injection, ophthalmic drops, or iontophoresis) that leverages the retina's natural anatomical connections to the brain, providing a less invasive and more cost-effective treatment approach.
3Productivity
If larger doses of dopamine replacement agents are administered, then efficacy is improved, but side effects increase
Solution Approach 1:
The patent achieves improved efficacy with reduced side effects by concentrating the agent delivery at the retinal level. The local administration allows for smaller, more precise doses to be effective in modulating retinal dopamine production, while avoiding the dose-related toxicity that occurs with systemic administration. The retinal dopamine system's downstream projections ensure brain effect without requiring high systemic doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for reduced side effects and increased efficacy by using smaller doses, potentially offering sustained relief from symptoms with minimal systemic impact, and may include the use of stem cells or light therapy for enhanced treatment outcomes.
Implementation Method 1
administering an agent that modulates neurotransmitter production or function... increasing dopamine production or inhibiting melatonin production
Implementation Method 2
using methods like intraocular injection, ophthalmic drops, or iontophoresis
Data Source
AI summary
A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.